Sep 24, 2024 08:06AM

Sep 24, 2024 08:00AM

Apr 11, 2022 08:06AM

Apr 11, 2022 08:00AM

Nov 24, 2021 08:16AM

Nov 24, 2021 08:16AM

Feb 18, 2021 07:00AM Seelos Therapeutics Announces Amendment of SLS-002 Agreement to Repurchase a Significant Portion of Royalties for SLS-002 (Intranasal Racemic Ketamine Program)

Jan 6, 2021 09:10AM

Jan 6, 2021 08:45AM

Oct 15, 2019 09:00AM

Oct 15, 2019 09:00AM

Aug 23, 2019 09:18AM

Jun 27, 2019 07:19AM

Jun 27, 2019 07:00AM Seelos Therapeutics Announces Acquisition of an Exclusive Worldwide License of Gene Therapy Program to Address Parkinson’s Disease from Duke University

Jun 27, 2019 07:00AM

May 21, 2019 08:30AM

May 21, 2019 08:30AM

Mar 29, 2019 06:14AM

Mar 28, 2019 05:00PM

Mar 28, 2019 05:00PM

Mar 7, 2019 08:09AM UPDATE: Seelos Therapeutics (SEEL) Announces Acquisition of License to IP from The UC Regents to Potential Disease-Modifying Parkinson's Disease Therapy Created at UCLA

Mar 7, 2019 08:00AM

Mar 7, 2019 08:00AM

Feb 19, 2019 08:00AM

Feb 19, 2019 08:00AM

Feb 19, 2019 07:45AM

Jan 25, 2019 09:00AM

Jan 24, 2019 08:01AM Seelos Therapeutics, Inc. Announces Successful Completion of its Merger with Apricus Biosciences, Inc. to Advance Late-Stage Pipeline of Products for Central Nervous System (CNS) Disorders

Jan 24, 2019 08:01AM

1,155,205 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All